Bionano Genomics (BNGO) Depreciation & Amortization (CF) (2017 - 2026)

Bionano Genomics has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $2.3 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 5.09% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 12.62% YoY) and the FY2025 annual result came in at $9.5 million, down 32.06% from the prior year.
• Depreciation & Amortization (CF) retreated to $2.3 million in Q1 2026 per BNGO's latest filing, from $2.3 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $3.6 million in Q3 2023 and troughed at $1.8 million in Q3 2025.
• A 5-year average of $2.6 million and a median of $2.4 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) jumped 393.3% in 2022, then plunged 36.74% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $2.8 million in 2022, then jumped by 30.01% to $3.6 million in 2023, then sank by 33.31% to $2.4 million in 2024, then fell by 2.54% to $2.3 million in 2025, then fell by 1.16% to $2.3 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.3 million, $2.3 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.